New Jersey Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on February 2, 2026

Feb. 2, 2026

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

GlobeNewswire

Feb. 2, 2026

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

GlobeNewswire

Feb. 2, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

GlobeNewswire

Feb. 2, 2026

DLH to Announce Fiscal 2026 First Quarter Financial Results

GlobeNewswire

Feb. 2, 2026

Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians

GlobeNewswire

Feb. 2, 2026

ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan

GlobeNewswire

Feb. 2, 2026

Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence

GlobeNewswire

Feb. 2, 2026

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

GlobeNewswire

Feb. 2, 2026

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

GlobeNewswire

Feb. 2, 2026

Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook

GlobeNewswire

Feb. 2, 2026

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis

GlobeNewswire

Feb. 2, 2026

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

GlobeNewswire

Feb. 2, 2026

Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease

GlobeNewswire

Feb. 2, 2026

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

GlobeNewswire

Feb. 2, 2026

Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial

GlobeNewswire

Feb. 2, 2026

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

GlobeNewswire

Feb. 2, 2026

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

GlobeNewswire

Feb. 2, 2026

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

GlobeNewswire

Feb. 2, 2026

Global Pharmaceutical Filtration Market Projected to Achieve 11.1% CAGR Through 2030

GlobeNewswire

Feb. 2, 2026

Sago Health Announces Rebrand to TriVoca Health

GlobeNewswire